Audit: QRS - MOTS-c for Health & Longevity

Audit conducted on 02/07/2026 05:02 using AI4L / Opus 4.8

Iterations

Summary

Items	Count
Total	91
Passed	84
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All content traces to the ER (protocol, benefits, risks, contraindications, monitoring).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“not from controlled trials”, “not established in humans”, “Unproven” mirror ER caution.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications and unproven-human-timeline framing preserved.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Categories map faithfully to ER sections.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No citations, IDs, or brand names introduced.
1.6	The QRS does not introduce new attributions.	🟢	No new attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Cautious, evidence-graded tone matches ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Objective and accessible throughout.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence, not prescriptions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No directive medical advice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Descriptive, non-prescriptive phrasing.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language used; technical terms glossed where present.
2.8	Information is presented in a concise and very compact manner	🟢	Compact card/table layout.
2.9	It DOES NOT address the reader directly	🟢	No direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing fits proactive audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Injectable, cold-chain protocol presented plainly.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Weighting reflects proactive audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim.	🟢	Uses “longevity” (title, at-a-glance); no “anti-aging”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt.	🟢	“subcutaneous injection”, “hypoglycemia” used; plain terms confined to at-a-glance per 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified (card/section headings, gate headings, tier labels, Monitoring column headers).	🟢	All fixed headings present and unmodified.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All expected variable spans present.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Non-addressed spans unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim.	🟢	High/Medium tiers hidden via display:none per 12.5/13.5; no false empty-state text.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol/tier labels match ER.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Labels faithful.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.).	🟢	No emoji indicators in body content.
4.5	The QRS is designed to render on one A4 page. Any section with more content than fits is condensed, not extended onto a second page.	🟢	Content condensed to fit one page.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment is first element (lines 2-14).
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing.	🟢	Delimited at lines 3 and 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in HTML comment.
5.4	All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML.	🟢	Only duration quoted (contains colon).
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: mots_c_2026-0702-0407_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.5.18
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”	🟢	qrs_creation_date: 2026-0702-0407
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc.	🟢	“Opus”.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname”	🟢	qrs_creator_ai_fullname: Opus 4.8
5.11	The full name of the AI consists of the nickname and the model version number and no additional qualifier.	🟢	“Opus 4.8”.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: mots_c_2026-0702-0407_Opus_QRS.html
5.13	All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required by YAML.	🟢	All values clean.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] followed by “ - Quick Reference Sheet”, HTML-entity-encoded as needed.	🟢	“MOTS-c for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic], with HTML entities encoded as needed.	🟢	“MOTS-c for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0702 → 07/02/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 4.8”.
6.5	No additional header content appears: no badge, version stamp, AKA line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only standard subline.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Distills the Conclusion (lines 395-399).
7.2	[at_a_glance] is no longer than 60 words	🟢	56 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each claim maps to Conclusion passages.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“energy factories”, “blood-sugar handling”; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial citations.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	From ER “Populations who should avoid” bullet (line 257).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Pregnancy/breastfeeding, children/adolescents, active cancer, unsupervised insulin diabetes, self-directed disease treatment, unverified product.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is an <li>.
8.4	Items are as concise as possible. No trailing explanations/rationale/attributions/citations; no content after em/en/hyphen dash.	🟢	Rationale (e.g., AMPK/mTOR) stripped.
8.5	Parenthetical qualifiers from the ER bullet ARE preserved, kept concise.	🟢	No essential qualifiers dropped.
8.6	When the ER uses ranking notation inside parens (e.g., “>”), normalize to a plain comma-separated list.	N/A	ER contraindication bullet uses no ranking notation.
8.7	If no [stop_items] are present the section is left empty	N/A	Contraindications are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	From ER glucose-lowering drug/supplement bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications	🟢	Glucose-lowering drugs and AMPK/glucose-lowering supplements; no overlap with contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each item is an <li>.
9.4	Items are as concise as possible. No trailing explanations/rationale; no content after em/en/hyphen dash.	🟢	Severity/consequence text stripped.
9.5	Parenthetical qualifiers (example drug lists, etc.) ARE preserved, kept concise.	🟢	Drug/supplement example lists preserved.
9.6	When the ER uses ranking notation inside parens, normalize to a plain comma-separated list.	N/A	No ranking notation in ER interaction bullets.
9.7	If no [caution_items] are present the section is left empty	N/A	Key interactions are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	From ER Therapeutic Protocol (lines 279-289).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, Frequency, Route.
10.3	If fewer than three distinct actionable aspects exist, unused sets are left empty and invisible.	N/A	Three actionable aspects exist.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content from the ER Protocol section.	🟢	All three cells populated and ER-derived.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Acute performance, metabolic changes, human timeline (ER line 330).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered acute → metabolic → human-unproven.
11.3	If fewer than three distinct time-to-effect aspects exist, unused sets are left empty and invisible.	N/A	Three aspects present.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content from the ER.	🟢	All populated and ER-derived.
11.5	If the ER does not provide any time-to-effect info, the section is removed completely from the Protocol Panel.	N/A	ER provides time-to-effect info.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	From ER Expected Benefits (lines 135-175).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four variables present.
12.3	Items are as concise as possible. No explanations, effect sizes, qualifiers, attributions, citations, or mechanisms.	🟢	Bare benefit statements only.
12.4	Parenthetical content is stripped, NOT preserved.	🟢	No parentheticals present.
12.5	If no items of a sub-section are present, the respective SPAN is set to display:none.	🟢	benefits_high and benefits_medium set to display:none.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	From ER Risks (lines 193-227).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four variables present.
13.3	Items are as concise as possible. No explanations, effect sizes, qualifiers, attributions, citations, or mechanisms.	🟢	Bare risk statements only.
13.4	Parenthetical content is stripped, NOT preserved.	🟢	No parentheticals present.
13.5	If no items of a sub-section are present, the respective SPAN is set to display:none.	🟢	risks_high and risks_medium set to display:none.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	From ER Monitoring table (lines 358-365).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 6 biomarkers listed with targets and rationale.
14.3	[monitoring_cadence] is populated with the cadence from the ER Monitoring section; not placeholder or empty.	🟢	Baseline, 4–6 weeks, then every 3–6 months (ER line 356).

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	From ER qualitative markers (lines 369-373).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 5 qualitative markers listed.

Issues 02/07/2026 05:02

Pass rate 100.00%. No issues found.

Issues 02/07/2026 04:57

1. 1.1 / 1.2 / 1.3 / 1.4 / 1.5 / 1.6 — QRS never populated: The QRS is an unmodified copy of the blank template; every content span still holds its literal placeholder, so no ER-derived claims, phrasing, categories, or attributions exist to validate.
2. 2.1–2.15 — No prose to assess tone/audience: All tone, voice, and audience-framing items fail because the QRS contains no written content — only template placeholders.
3. 4.1 / 4.2 / 4.3 / 4.5 — Formatting unpopulated: Empty-state phrasing, bold labels, and one-page condensation were never applied because no section was filled from the ER.
4. 5.4 / 5.13 — Unnecessary quotes on duration: duration: "00:00" (line 10) is quoted but contains no colon/bracket/special character requiring YAML quoting.
5. 6.1 / 6.2 / 6.3 / 6.4 — Header fields unfilled: [page_title], [header_topic], [header_subline_date], and [header_subline_model] remain placeholders instead of “MOTS-c for Health & Longevity - Quick Reference Sheet”, the topic, “07/02/2026”, and “Opus 4.8”.
6. 7.1–7.6 — At-A-Glance empty: [at_a_glance] (line 433) was never written; no summary of the ER Conclusion exists.
7. 8.1–8.5 — Contraindications empty: [stop_items] (line 541) was never populated from the ER “populations who should avoid” contraindications.
8. 9.1–9.5 — Key Interactions empty: [caution_items] (line 547) was never populated from the ER interactions (glucose-lowering drugs, additive supplements, etc.).
9. 10.1–10.4 — Protocol empty: All action label/value/sub spans (lines 444–472) remain placeholders; no dose/route/frequency/cycling detail from the ER Therapeutic Protocol was transferred.
10. 11.1–11.4 — Time to Effect empty: All time label/value/sub spans (lines 483–511) remain placeholders; the ER’s time-to-effect content was not transferred.
11. 12.1–12.5 — Benefits empty: All benefits tier spans (lines 521–531) remain placeholders; empty High/Medium tiers were not hidden and populated tiers were not filled.
12. 13.1–13.5 — Risks empty: All risks tier spans (lines 558–568) remain placeholders; empty High/Medium tiers were not hidden and populated tiers were not filled.
13. 14.1–14.3 — Monitoring empty: The marker row and cadence spans (lines 587–600) remain placeholders; none of the ER biomarkers or the monitoring cadence were transferred.
14. 15.1 / 15.2 — Qualitative Assessment empty: [qualitative_item_#] (line 609) remains a placeholder; none of the ER qualitative markers were listed.

Fixes 02/07/2026 05:00

1. 6.1 / 6.2 / 6.3 / 6.4 — Header fields populated: Set [page_title] to “MOTS-c for Health & Longevity - Quick Reference Sheet”, [header_topic] to “MOTS-c for Health & Longevity”, [header_subline_date] to “07/02/2026”, and [header_subline_model] to “Opus 4.8”.
2. 7.1–7.6 — At-A-Glance written: Populated [at_a_glance] with a plain-language, ~55-word execution summary of the ER Conclusion, with no trials, effect sizes, or statistics.
3. 10.1–10.4 — Protocol populated: Filled the three action sets from the ER Therapeutic Protocol — Dose (5–10 mg), Frequency (a few times per week), Route (subcutaneous injection) — with derived sub-lines.
4. 11.1–11.4 — Time to Effect populated: Filled the three time sets from the ER Practical Considerations — acute performance after single doses, metabolic changes over days to weeks, and unproven human timeline.
5. 12.1–12.5 — Benefits populated / empty tiers hidden: Filled Low and Speculative benefit spans from the ER; set the empty High and Medium spans to display:none rather than empty-state text.
6. 13.1–13.5 — Risks populated / empty tiers hidden: Filled Low and Speculative risk spans from the ER; set the empty High and Medium spans to display:none.
7. 8.1–8.5 — Contraindications populated: Filled [stop_items] as <li> list from the ER “populations who should avoid” set (pregnancy/breastfeeding, children, active cancer, unsupervised insulin-treated diabetes, self-directed disease treatment, unverified product).
8. 9.1–9.5 — Key Interactions populated: Filled [caution_items] as <li> list from the ER interactions — glucose-lowering prescription drugs and glucose-lowering/AMPK-activating supplements, with named examples preserved.
9. 14.1–14.3 — Monitoring populated: Filled the biomarker rows (fasting glucose, insulin, HbA1c, lipid panel, hs-CRP, CMP) with targets and rationale, and set [monitoring_cadence] from the ER (baseline, 4–6 weeks, then every 3–6 months).
10. 15.1 / 15.2 — Qualitative Assessment populated: Filled the qualitative items from the ER Monitoring section (energy/fatigue, exercise capacity, body composition, metabolic well-being, absence of injection-site/hypoglycemia problems).
11. 1.1–1.6 / 2.1–2.15 / 4.1–4.5 — Content now ER-derived: With all spans populated from the source ER, the general-rule, tone/audience, and formatting items are now backed by actual ER-supported content instead of raw placeholders.